MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525005 | Name: Emiglitate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Emiglitate, a deoxynojirimycin derivative, is an α-glucosidase inhibitor that is a powerful inhibitor of glucose-induced insulin release.

Chemical Structure

Emiglitate
Emiglitate
CAS#80879-63-6

Theoretical Analysis

MedKoo Cat#: 525005

Name: Emiglitate

CAS#: 80879-63-6

Chemical Formula: C17H25NO7

Exact Mass: 355.1631

Molecular Weight: 355.38

Elemental Analysis: C, 57.45; H, 7.09; N, 3.94; O, 31.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Emiglitate; Emiglitate [INN:BAN]; Emiglitatum; BAY o 1248; EINECS 279-613-2;Emiglitatum [Latin]; Emiglitate; UNII-PF8AB2IBUM.
IUPAC/Chemical Name
1,5-Dideoxy-1,5-((2-(4-(ethoxycarbonyl)phenoxy)ethyl)imino)-D-glucitol
InChi Key
NWWORXYTJRPSMC-CAOSSQGBSA-N
InChi Code
InChI=1S/C17H25NO7/c1-2-24-17(23)11-3-5-12(6-4-11)25-8-7-18-9-14(20)16(22)15(21)13(18)10-19/h3-6,13-16,19-22H,2,7-10H2,1H3/t13-,14-,15+,16+/m0/s1
SMILES Code
C1[C@@H]([C@@H](O)[C@@H]([C@H](CO)[N@@]1CCOc1ccc(cc1)C(OCC)=O)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 355.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mosén H, Salehi A, Henningsson R, Lundquist I. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activities in parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93. PubMed PMID: 17003269. 2: Depre C, Hue L. Inhibition of glycogenolysis by a glucose analogue in the working rat heart. J Mol Cell Cardiol. 1997 Aug;29(8):2253-9. PubMed PMID: 9281456. 3: Lundquist I, Panagiotidis G, Salehi A. Islet acid glucan-1,4-alpha-glucosidase: a putative key enzyme in nutrient-stimulated insulin secretion. Endocrinology. 1996 Apr;137(4):1219-25. PubMed PMID: 8625892. 4: Salehi A, Lundquist I. Modulation of islet G-proteins, alpha-glucosidehydrolase inhibition and insulin release stimulated by various secretagogues. Biosci Rep. 1996 Feb;16(1):23-34. PubMed PMID: 8861537. 5: Salehi A, Panagiotidis G, Borg LA, Lundquist I. The pseudotetrasaccharide acarbose inhibits pancreatic islet glucan-1,4-alpha-glucosidase activity in parallel with a suppressive action on glucose-induced insulin release. Diabetes. 1995 Jul;44(7):830-6. PubMed PMID: 7789651. 6: Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest. 1994 Aug;24 Suppl 3:3-10. Review. PubMed PMID: 8001624. 7: Salehi A, Lundquist I. Changes in islet glucan-1,4-alpha-glucosidase activity modulate sulphonylurea-induced but not cholinergic insulin secretion. Eur J Pharmacol. 1993 Oct 19;243(2):185-91. PubMed PMID: 8276068. 8: Salehi A, Lundquist I. Islet glucan-1,4-alpha-glucosidase: differential influence on insulin secretion induced by glucose and isobutylmethylxanthine in mice. J Endocrinol. 1993 Sep;138(3):391-400. PubMed PMID: 7506286. 9: Lembcke B, Fölsch UR, Gatzemeier W, Lücke B, Ebert R, Siegel E, Creutzfeldt W. Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers. Eur J Clin Pharmacol. 1991;41(6):561-7. PubMed PMID: 1815967. 10: Lembcke B, Lamberts R, Wöhler J, Creutzfeldt W. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404. PubMed PMID: 1775731. 11: Dimitriadis G, Hatziagelaki E, Ladas S, Linos A, Hillebrand I, Raptis S. Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 1988 Feb;18(1):33-8. PubMed PMID: 3130257. 12: Serrano-Rios M, Sabán J, Navascués I, Cañizo JF, Hillebrand I. Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1988 Jan 7;4(2):111-6. PubMed PMID: 3277827. 13: Gerard J, Hillebrand I, Lefèbvre PJ. Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics. Int J Clin Pharmacol Ther Toxicol. 1987 Sep;25(9):483-8. PubMed PMID: 3316059. 14: Kennedy FP, Miles JM, Heiling V, Gerich JE. The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers. Clin Exp Pharmacol Physiol. 1987 Aug;14(8):633-40. PubMed PMID: 3326689. 15: Federlin KF, Mehlburger L, Hillebrand I, Laube H. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics. Acta Diabetol Lat. 1987 Jul-Sep;24(3):213-21. PubMed PMID: 3687313. 16: Omar MA, Seedat MA, Hillebrand I. The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients. S Afr Med J. 1987 Apr 4;71(7):422-3. PubMed PMID: 2951875. 17: Hillebrand I. Pharmacological modification of digestion and absorption. Diabet Med. 1987 Mar-Apr;4(2):147-50. PubMed PMID: 2952432. 18: Lembcke B, Löser C, Fölsch UR, Wöhler J, Creutzfeldt W. Adaptive responses to pharmacological inhibition of small intestinal alpha-glucosidases in the rat. Gut. 1987;28 Suppl:181-7. PubMed PMID: 3319810; PubMed Central PMCID: PMC1434562. 19: Lee SM, Bustamante S, Flores C, Bezerra J, Goda T, Koldovský O. Chronic effects of an alpha-glucosidase inhibitor (Bay o 1248) on intestinal disaccharidase activity in normal and diabetic mice. J Pharmacol Exp Ther. 1987 Jan;240(1):132-7. PubMed PMID: 3100764. 20: Samulitis BK, Goda T, Lee SM, Koldovský O. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res. 1987;13(8):517-24. PubMed PMID: 2962844.